Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.

Neuroendocrinology

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D.
PMID: 28391265
Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 08.

No abstract available.

Cite
Oberg K, Couvelard A, Delle Fave G, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology. 2017;105(3):201-211doi: 10.1159/000472254.
Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., Pape, U. F., Perren, A., Rindi, G., Ruszniewski, P., Scoazec, J. Y., Welin, S., Wiedenmann, B., Ferone, D. (2017). ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology, 105(3), 201-211. https://doi.org/10.1159/000472254
Oberg, Kjell, et al. "ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers." Neuroendocrinology vol. 105,3 (2017): 201-211. doi: https://doi.org/10.1159/000472254
Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 08. PMID: 28391265.
Copy Download .nbib Format: NLM
OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?.

Thrombosis research

Faille D, Ajzenberg N, de Chaisemartin L, Granger V, Chollet-Martin S, de Raucourt E, Hammel P, Lévy P, Ruszniewski P, Rebours V.
PMID: 27161678
Thromb Res. 2016 Apr;140:S170-1. doi: 10.1016/S0049-3848(16)30123-2. Epub 2016 Apr 08.

INTRODUCTION: Venous thrombo-embolic events (VTE) occur frequently in patients with pancreatic cancer and contribute to elevated morbidity and mortality. Clinical risk factors for thrombosis such as cancer stage and tumor grade have been clearly identified. Recently, several biomarkers have...

Cite
Faille D, Ajzenberg N, de Chaisemartin L, et al. OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?. Thromb Res. 2016;140:S170-1doi: 10.1016/S0049-3848(16)30123-2.
Faille, D., Ajzenberg, N., de Chaisemartin, L., Granger, V., Chollet-Martin, S., de Raucourt, E., Hammel, P., Lévy, P., Ruszniewski, P., & Rebours, V. (2016). OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?. Thrombosis research, 140S170-1. https://doi.org/10.1016/S0049-3848(16)30123-2
Faille, D, et al. "OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?." Thrombosis research vol. 140 (2016): S170-1. doi: https://doi.org/10.1016/S0049-3848(16)30123-2
Faille D, Ajzenberg N, de Chaisemartin L, Granger V, Chollet-Martin S, de Raucourt E, Hammel P, Lévy P, Ruszniewski P, Rebours V. OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?. Thromb Res. 2016 Apr;140:S170-1. doi: 10.1016/S0049-3848(16)30123-2. Epub 2016 Apr 08. PMID: 27161678.
Copy Download .nbib Format: NLM
[Caregivers and those cared for in cancer].

Soins; la revue de reference infirmiere

Ruszniewski M.
PMID: 11949174
Soins. 2002 Mar;(663):34-5.

No abstract available.

Cite
Ruszniewski M. Soignants et soignés face à la maladie cancéreuse. [Caregivers and those cared for in cancer]. Soins. 2002;(663):34-5
Ruszniewski, M. (2002). Soignants et soignés face à la maladie cancéreuse. [Caregivers and those cared for in cancer]. Soins; la revue de reference infirmiere, (663), 34-5.
Ruszniewski, Martine. "Soignants et soignés face à la maladie cancéreuse." [Caregivers and those cared for in cancer]. Soins; la revue de reference infirmiere vol. ,663 (2002): 34-5.
Ruszniewski M. Soignants et soignés face à la maladie cancéreuse. [Caregivers and those cared for in cancer]. Soins. 2002 Mar;(663):34-5. French. PMID: 11949174.
Copy Download .nbib Format: NLM
Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours.

Clinical molecular pathology

Terris B, Fléjou JF, Dubois S, Ruszniewski P, Scoazec JY, Belghiti J, Potet F, Bernades P, Mignon M, Hénin D.
PMID: 16696075
Clin Mol Pathol. 1996 Aug;49(4):M203-8. doi: 10.1136/mp.49.4.m203.

Aims/background-To analyse the different isoforms of CD44 in various types of endocrine pancreatic and gut carcinoid tumours and to investigate the relation between their expression and tumour dissemination. This study was prompted by the recent observation that inappropriate splicing...

Cite
Terris B, Fléjou JF, Dubois S, et al. Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Clin Mol Pathol. 1996;49(4):M203-8doi: 10.1136/mp.49.4.m203.
Terris, B., Fléjou, J. F., Dubois, S., Ruszniewski, P., Scoazec, J. Y., Belghiti, J., Potet, F., Bernades, P., Mignon, M., & Hénin, D. (1996). Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Clinical molecular pathology, 49(4), M203-8. https://doi.org/10.1136/mp.49.4.m203
Terris, B, et al. "Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours." Clinical molecular pathology vol. 49,4 (1996): M203-8. doi: https://doi.org/10.1136/mp.49.4.m203
Terris B, Fléjou JF, Dubois S, Ruszniewski P, Scoazec JY, Belghiti J, Potet F, Bernades P, Mignon M, Hénin D. Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Clin Mol Pathol. 1996 Aug;49(4):M203-8. doi: 10.1136/mp.49.4.m203. PMID: 16696075; PMCID: PMC408059.
Copy Download .nbib Format: NLM
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.
PMID: 31407000
Ann Oncol. 2019 Nov 01;30(11):1846. doi: 10.1093/annonc/mdz219.

No abstract available.

Cite
Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019;30(11):1846doi: 10.1093/annonc/mdz219.
Kulke, M. H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J. W., De Herder, W. W., Pavel, M., Degtyarev, E., Brase, J. C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P., & Yao, J. C. (2019). A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 30(11), 1846. https://doi.org/10.1093/annonc/mdz219
Kulke, M H, et al. "A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial." Annals of oncology : official journal of the European Society for Medical Oncology vol. 30,11 (2019): 1846. doi: https://doi.org/10.1093/annonc/mdz219
Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 Nov 01;30(11):1846. doi: 10.1093/annonc/mdz219. PMID: 31407000.
Copy Download .nbib Format: NLM
[No title available]

The Lancet. Oncology

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP.
PMID: 34793718
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.

FUNDING: Advanced Accelerator Applications, a Novartis company.

Cite
Strosberg JR, Caplin ME, Kunz PL, et al. . Lancet Oncol. 2021;22(12):1752-1763doi: 10.1016/S1470-2045(21)00572-6.
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., Grande, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Mariani, M. F., Demange, A., Mutevelic, S., Krenning, E. P. (2021). . The Lancet. Oncology, 22(12), 1752-1763. https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg, Jonathan R, et al. "." The Lancet. Oncology vol. 22,12 (2021): 1752-1763. doi: https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. . Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718.
Copy Download .nbib Format: NLM
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.

Endocrine-related cancer

De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L.
PMID: 33979778
Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034.

A rechallenge is common after the initial efficacy of alkylating-based chemotherapy (ALK) in pancreatic neuroendocrine tumors (PanNET). High MGMT expression seems associated with a lower response to ALK. We aimed to evaluate the efficacy and toxicity of ALK rechallenge...

Cite
De Rycke O, Walter T, Perrier M, et al. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2021;28(7):457-466doi: 10.1530/ERC-21-0034.
De Rycke, O., Walter, T., Perrier, M., Hentic, O., Lombard-Bohas, C., Coriat, R., Cadiot, G., Couvelard, A., Ruszniewski, P., Cros, J., & de Mestier, L. (2021). Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocrine-related cancer, 28(7), 457-466. https://doi.org/10.1530/ERC-21-0034
De Rycke, Ophélie, et al. "Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors." Endocrine-related cancer vol. 28,7 (2021): 457-466. doi: https://doi.org/10.1530/ERC-21-0034
De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034. PMID: 33979778.
Copy Download .nbib Format: NLM
Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study.

European journal of endocrinology

Le Bras M, Leclerc H, Rousseau O, Goudet P, Cuny T, Castinetti F, Bauters C, Chanson P, Tabarin A, Gaujoux S, Christin-Maitre S, Ruszniewski P, Borson-Chazot F, Guilhem I, Caron P, Goichot B, Beckers A, Delemer B, Raingeard I, Vergès B, Smati S, Wargny M, Cariou B, Hadjadj S.
PMID: 34636744
Eur J Endocrinol. 2021 Nov 26;185(6):863-873. doi: 10.1530/EJE-21-0630.

OBJECTIVE: Pituitary adenoma (PA) is one of the three major components of multiple endocrine neoplasia type 1 (MEN1). Recent studies have suggested that MEN1-associated PAs are less aggressive than initially estimated. We propose an analysis of the outcome of...

Cite
Le Bras M, Leclerc H, Rousseau O, et al. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. Eur J Endocrinol. 2021;185(6):863-873doi: 10.1530/EJE-21-0630.
Le Bras, M., Leclerc, H., Rousseau, O., Goudet, P., Cuny, T., Castinetti, F., Bauters, C., Chanson, P., Tabarin, A., Gaujoux, S., Christin-Maitre, S., Ruszniewski, P., Borson-Chazot, F., Guilhem, I., Caron, P., Goichot, B., Beckers, A., Delemer, B., Raingeard, I., Vergès, B., Smati, S., Wargny, M., Cariou, B., & Hadjadj, S. (2021). Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. European journal of endocrinology, 185(6), 863-873. https://doi.org/10.1530/EJE-21-0630
Le Bras, Maelle, et al. "Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study." European journal of endocrinology vol. 185,6 (2021): 863-873. doi: https://doi.org/10.1530/EJE-21-0630
Le Bras M, Leclerc H, Rousseau O, Goudet P, Cuny T, Castinetti F, Bauters C, Chanson P, Tabarin A, Gaujoux S, Christin-Maitre S, Ruszniewski P, Borson-Chazot F, Guilhem I, Caron P, Goichot B, Beckers A, Delemer B, Raingeard I, Vergès B, Smati S, Wargny M, Cariou B, Hadjadj S. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. Eur J Endocrinol. 2021 Nov 26;185(6):863-873. doi: 10.1530/EJE-21-0630. PMID: 34636744.
Copy Download .nbib Format: NLM
Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?.

Endocrine connections

Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V.
PMID: 28069898
Endocr Connect. 2017 Jan;6(1):33-38. doi: 10.1530/EC-16-0092. Epub 2017 Jan 09.

BACKGROUND: Visual semi-quantitative assessment of liver tumour burden for neuroendocrine tumour liver metastases is often used in patient management and outcome. However, published data on the reproducibility of these evaluations are lacking.OBJECTIVE: The aim of this study was to...

Cite
Zappa M, Hentic O, Vullierme MP, et al. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?. Endocr Connect. 2017;6(1):33-38doi: 10.1530/EC-16-0092.
Zappa, M., Hentic, O., Vullierme, M. P., Lagadec, M., Ronot, M., Ruszniewski, P., & Vilgrain, V. (2017). Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?. Endocrine connections, 6(1), 33-38. https://doi.org/10.1530/EC-16-0092
Zappa, Magaly, et al. "Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?." Endocrine connections vol. 6,1 (2017): 33-38. doi: https://doi.org/10.1530/EC-16-0092
Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?. Endocr Connect. 2017 Jan;6(1):33-38. doi: 10.1530/EC-16-0092. Epub 2017 Jan 09. PMID: 28069898; PMCID: PMC5302166.
Copy Download .nbib Format: NLM
Ionic Porous Organic Polymers Based on Functionalized Tetraarylborates.

Polymers

Tomaszewski P, Wiszniewski M, Gontarczyk K, Wieciński P, Durka K, Luliński S.
PMID: 31234284
Polymers (Basel). 2019 Jun 21;11(6). doi: 10.3390/polym11061070.

Lithium tetrakis(4-boronatoaryl)borates were subjected to polycondensation reactions with selected polyhydroxyl monomers such as 2,3,6,7,10,11-hexahydroxytriphenylene (HHTP) and 2,3,6,7-tetrahydroxy-9,10-dimethylanthracene (THDMA). Obtained boronate-type ionic porous polymers

Cite
Tomaszewski P, Wiszniewski M, Gontarczyk K, et al. Ionic Porous Organic Polymers Based on Functionalized Tetraarylborates. Polymers (Basel). 2019;11(6)doi: 10.3390/polym11061070.
Tomaszewski, P., Wiszniewski, M., Gontarczyk, K., Wieciński, P., Durka, K., & Luliński, S. (2019). Ionic Porous Organic Polymers Based on Functionalized Tetraarylborates. Polymers, 11(6), . https://doi.org/10.3390/polym11061070
Tomaszewski, Patryk, et al. "Ionic Porous Organic Polymers Based on Functionalized Tetraarylborates." Polymers vol. 11,6 (2019). doi: https://doi.org/10.3390/polym11061070
Tomaszewski P, Wiszniewski M, Gontarczyk K, Wieciński P, Durka K, Luliński S. Ionic Porous Organic Polymers Based on Functionalized Tetraarylborates. Polymers (Basel). 2019 Jun 21;11(6). doi: 10.3390/polym11061070. PMID: 31234284; PMCID: PMC6630441.
Copy Download .nbib Format: NLM
Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis.

Case reports in gastroenterology

de Mestier L, Neuzillet C, Hentic O, Kianmanesh R, Hammel P, Ruszniewski P.
PMID: 22649333
Case Rep Gastroenterol. 2012 Jan;6(1):205-10. doi: 10.1159/000338740. Epub 2012 Apr 30.

Peritoneal carcinomatosis is a well-known factor of poor prognosis in patients with digestive adenocarcinomas. Peritoneal dissemination may also occur in midgut well-differentiated neuroendocrine tumors, but its influence on survival is ill-defined. We report here the history of a 64-year-old...

Cite
de Mestier L, Neuzillet C, Hentic O, et al. Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis. Case Rep Gastroenterol. 2012;6(1):205-10doi: 10.1159/000338740.
de Mestier, L., Neuzillet, C., Hentic, O., Kianmanesh, R., Hammel, P., & Ruszniewski, P. (2012). Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis. Case reports in gastroenterology, 6(1), 205-10. https://doi.org/10.1159/000338740
de Mestier, Louis, et al. "Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis." Case reports in gastroenterology vol. 6,1 (2012): 205-10. doi: https://doi.org/10.1159/000338740
de Mestier L, Neuzillet C, Hentic O, Kianmanesh R, Hammel P, Ruszniewski P. Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis. Case Rep Gastroenterol. 2012 Jan;6(1):205-10. doi: 10.1159/000338740. Epub 2012 Apr 30. PMID: 22649333; PMCID: PMC3362188.
Copy Download .nbib Format: NLM
[No title available]

The Lancet. Oncology

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP.
PMID: 34793718
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.

FUNDING: Advanced Accelerator Applications, a Novartis company.

Cite
Strosberg JR, Caplin ME, Kunz PL, et al. . Lancet Oncol. 2021;22(12):1752-1763doi: 10.1016/S1470-2045(21)00572-6.
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., Grande, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Mariani, M. F., Demange, A., Mutevelic, S., Krenning, E. P. (2021). . The Lancet. Oncology, 22(12), 1752-1763. https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg, Jonathan R, et al. "." The Lancet. Oncology vol. 22,12 (2021): 1752-1763. doi: https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. . Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries